Impact of different sequencing strategies of talazoparib and carboplatin combination upon efficacy and toxicity in BRCA-wild type and BRCA-mutant triple-negative breast cancer models. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback